This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to treatment (refractory). Abemaciclib, a type of cyclin-dependent kinase inhibitor, blocks certain proteins, which may help keep tumor cells from growing. 5-fluorouracil, a type of antimetabolite, stops cells from making deoxyribonucleic acid (DNA) and may kill tumor cells. Giving abemaciclib in combination with 5-fluorouracil may be safe, tolerable, and/or effective in treating patients with metastatic and refractory colorectal cancer.

Start Date31 Oct 2025

Sponsor / Collaborator

National Cancer Institute

NCT06498648

/ RecruitingPhase 1/2IIT

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase 1/2 trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with leiomyosarcoma or dedifferentiated liposarcoma (phase 2). Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Giving abemaciclib with gemcitabine may be safe and effective when compared to treatment with gemcitabine and docetaxel for patients with advanced or metastatic soft tissue sarcoma or leiomyosarcoma or dedifferentiated liposarcoma.

Start Date14 Oct 2025

Sponsor / Collaborator

National Cancer Institute

NCT06810492

/ Not yet recruitingNot ApplicableIIT

A Single-arm Exploratory Study of the Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment of HR+/HER2- Early Breast Cancer

To explore the efficacy and safety of CDK4/6 inhibitors combined with endocrine neoadjuvant therapy for stage II-III HR-positive/HER2-negative breast cancer.
This study adopts a single-arm, open-label design, and plans to include 40 patients with stage II-III HR+/HER2- breast cancer.

Start Date01 Apr 2025

Sponsor / Collaborator

Hubei Cancer Hospital

100 Clinical Results associated with Abemaciclib

100 Translational Medicine associated with Abemaciclib

100 Patents (Medical) associated with Abemaciclib

1,439

Literatures (Medical) associated with Abemaciclib

01 Jun 2025·Clinical Genitourinary Cancer

CDK4/6 Inhibition With Abemaciclib in Patients With Previously Treated Advanced Renal Cell Carcinoma

Article

Author: Xu, Wenxin ; Kaelin, William G ; McGregor, Bradley A ; Choueiri, Toni K ; McDermott, David ; Xie, Wanling ; Berg, Stephanie A ; Signoretti, Sabina ; Viswanathan, Srinivas R

BACKGROUND:

Preclincal data provide a rationale for cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors alone and in combination with HIF-2α inhibitors in treatment of clear cell renal cell carcinoma (ccRCC), with randomized phase 2 clinical trials currently open exploring the combination of palbociclib with belzutifan vs belzutifan in treatment resistant ccRCC (NCT05468697). However, single agent activity for CDK4/6 inhibitors in ccRCC has not been reported. In this multi-center phase 1b clinical trial (NCT04627064), we investigated the safety and efficacy of monotherapy with abemaciclib, an oral CDK4/6 inhibitor in patients with advanced pretreated RCC.

METHODS:

Adult patients with advanced RCC with a clear cell component and ECOG status of ≤ 2 progressing after at least 1 prior regimen including immunotherapy and a VEGFR TKI received abemaciclib 200 mg twice daily in 4-week cycles until progression or unacceptable toxicity. The primary objective was to evaluate the objective response rate (ORR) of abemaciclib with a secondary endpoint of safety. First imaging was performed after 8 weeks or 2 cycles. Response was assessed per RECIST 1.1 and toxicity graded per CTCAE v5.0.

RESULTS:

Eleven patients were enrolled between December 31, 2020 and October 03, 2023. Median age was 62 years (range 54-68); 73% (n = 8) had IMDC intermediate risk disease and 1 patient had translocation RCC with a clear cell component. Median number of prior therapies was 4 (range 1-9). ORR was 0% (0/11; 8 progressive disease, 1 stable disease stopping for clinical progression, 2 not evaluable with clinical progression). About 27% (n = 3) experienced grade ≥3 treatment-related adverse events (diarrhea n = 1, nausea n = 1, neutropenia n = 1).

CONCLUSION:

In patients with heavily pretreated metastatic RCC, abemaciclib monotherapy had no clinically meaningful activity without new toxicity signals. This data will offer important insight into interpretation of results for ongoing trials exploring CDK4/6 inhibition in combination with HIF-2α inhibitors and immunotherapy.

01 Apr 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

CYP3A4 activity variations can lead to stratified metabolism of abemaciclib

Article

Author: Chen, Zhong-Xi ; Qian, Jian-Chang ; Zhou, Qi ; Xu, Xiao-Yu ; Luo, Jian-Chao ; Zhong, Yun-Shan ; Chen, Jing ; Zhang, Zhe-Yan ; Jin, Le-Hao

The interindividual variability of CYP3A4 activity complicates precision pharmacotherapy, particularly for drugs with narrow therapeutic windows. To explore the relationship between CYP3A4 polymorphisms and metabolic phenotypes, this study used abemaciclib as a probe substrate within a translational framework. The in vitro platform combined a reconstituted enzyme catalysis system for high-throughput inhibitor screening with UPLC-MS/MS metabolic profiling. In vivo pharmacokinetic studies were performed in female SD rats, with optimized sampling during the elimination phase. Human CYP3A4 baculosomes were engineered using baculovirus-mediated expression in Sf21 cells to investigate genetic influences on metabolic variability. Molecular docking and dynamics simulations were also performed to investigate structural differences in inhibitory activity. Results showed that letrozole significantly inhibited CYP3A4-mediated abemaciclib metabolism, reduced its clearance and increased its area under the blood concentration-time curve (AUC) and maximum blood concentration (C_max) through mixed inhibition. Moreover, CYP3A4 polymorphisms substantially impacted abemaciclib pharmacokinetics. Kinetic simulations revealed that the CYP3A4.28 variant formed a stable complex with letrozole, enhancing inhibition, while the CYP3A4.30 variant lost catalytic activity. These findings underscored the critical role of CYP3A4 activity and genetic polymorphisms in drug metabolism and highlighted the necessity for personalized treatment approaches.

01 Apr 2025·MOLECULAR DIVERSITY

Targeting AFP-RARβ complex formation: a potential strategy for treating AFP-positive hepatocellular carcinoma

Article

Author: Dev, Radul R ; Soman, Sowmya ; Banjan, Bhavya ; Raju, Rajesh ; Vishwakarma, Riya ; Rehman, Niyas ; Kalath, Haritha ; Kumar, Pankaj ; Revikumar, Amjesh ; Abhinand, Chandran S ; Ramakrishnan, Krishnapriya

Alpha-fetoprotein (AFP) is a glycoprotein primarily expressed during embryogenesis, with declining levels postnatally. Elevated AFP levels correlate with pathological conditions such as liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Recent investigations underscore AFP's intracellular role in HCC progression, wherein it forms complexes with proteins like Phosphatase and tensin homolog (PTEN), Caspase 3 (CASP3), and Retinoic acid receptors and Retinoid X receptors (RAR/RXR). RAR and RXR regulate gene expression linked to cell death and tumorigenesis in normal physiology. AFP impedes RAR/RXR dimerization, nuclear translocation, and function, promoting gene expression favoring cancer progression in HCC that provoked us to target AFP as a drug candidate. Despite extensive studies, inhibitors targeting AFP to disrupt complex formation and activities remain scarce. In this study, employing protein-protein docking, amino acid residues involved in AFP-RARβ interaction were identified, guiding the definition of AFP's active site for potential inhibitor screening. Currently, kinase inhibitors play a significant role in cancer treatment and, the present study explores the potential of repurposing FDA-approved protein kinase inhibitors to target AFP. Molecular docking with kinase inhibitors revealed Lapatinib as a candidate drug of the AFP-RARβ complex. Molecular dynamics simulations and binding energy calculations, employing Mechanic/Poisson-Boltzmann Surface Area (MM-PBSA), confirmed Lapatinib's stability with AFP. The study suggests Lapatinib's potential in disrupting the AFP-RARβ complex, providing a promising avenue for treating molecularly stratified AFP-positive HCC or its early stages.

338

News (Medical) associated with Abemaciclib

27 Mar 2025

·sermonixpharma.com

Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics

COLUMBUS, Ohio and CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced a strategic collaboration to optimize Regor’s proprietary, cutting-edge rCARD™ (Regor Computer Accelerated Rational Discovery) platform for identification of novel targets and therapeutics that fulfill unmet patient clinical needs and preferences in the breast oncology arena. The partnership will unite the key core competencies of both organizations to leverage expertise from early discovery through preclinical, clinical, and commercial launch, resulting in treatments that deliver on the promise of fulfilling on efficacy but also developing therapies with tolerability and quality of life profiles that are aligned with patient priorities and concerns. With a Phase 3 asset – oral lasofoxifene – in development for the treatment of ESR1-mutated ER+ HER2- mBC, the Sermonix team has expertise within the clinical drug development and commercialization arena and understands the landscape and value proposition of new treatments, which are requirements for launch success and adoption by both patients and health care providers. Patient insights and unmet needs within the arena of onco-sexuality and cardio oncology, in addition to patient concerns with respect to bone health, have been increasing in importance and are areas for which Sermonix also has expertise and interest in exploring. These areas are currently gaps within the breast cancer treatment patient arena and hold great concern for patients as breast cancer potentially evolves from a lethal to a chronic disease. Regor’s leading rCARD™ platform empowers drug discovery and development from target identification and validation, molecular design and optimization, to translational research and clinical development with unprecedented speed, efficiency, and success rate. “Regor’s translational to clinical approach – and then confirmation of clinical impact – is one we greatly admire and is producing molecules for development that will be best in class from both an efficacy and tolerability perspective,” said Dr. David Portman, Sermonix founder and chief executive officer. “At Sermonix, we believe patients deserve not only highly efficacious treatments, but also ones that are well tolerated and potentially improve quality of life for breast cancer patients. Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone, and cardiovascular health would be fulfilling on the promise of optimized drug development. It is an honor to collaborate with Regor in that shared mission.” Sermonix is currently enrolling its Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-3) study, comparing targeted lasofoxifene in combination with the CDK 4/6 inhibitor abemaciclib versus fulvestrant plus abemaciclib in pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. About Regor Therapeutics GroupRegor Therapeutics Group is a clinical-stage biotechnology company, headquartered in Cambridge, MA and with operations in Houston, TX, San Diego, CA, and Shanghai, China. Regor is developing innovative and clinically differentiated medicines to address large unmet needs in oncology, metabolism, and auto-immunity. Regor is powered by the highly efficient drug discovery engine rCARD™ (Regor Computer Accelerated Rational Discovery) that enables rapid prototyping and validation of candidate molecules. This rapid approach to developing small molecules against high-profile targets is the creation of the four cofounders who collectively brought decades of experience in leading US biopharma and were previously the named inventors of 4 FDA-approved medicines. The power of the rCARD™ platform and approach has been highlighted by out-licensing deals with top companies, including Roche/Genentech on next-gen CDK oncology agents RGT-419B and RGT-587 (now GDC-4198 and GDC-0587) in late 2024.To learn more about Regor, please visit us at www.regor.com.

Phase 3

25 Mar 2025

·www.pharmaceutical-technology.com

Sermonix and Regor to enhance breast cancer treatment options

The partnership aims to optimise Regor’s platform to identify targets and treatments that meet the individuals’ requirements and preferences. Credit: aslysun/Shutterstock. Sermonix Pharmaceuticals and Regor Therapeutics have announced a strategic partnership to discover and develop therapeutics in the breast oncology area. The partnership aims for the optimisation of the Regor Computer Accelerated Rational Discovery (rCARD) platform to identify new targets and treatments that meet individuals’ clinical requirements and preferences. It brings together the strengths of both companies, combining expertise from early discovery to commercial launch. This synergy is expected to yield treatments that not only demonstrate efficacy but also offer improved quality of life and tolerability. Regor’s rCARD platform is designed to accelerate the discovery and development of therapies from target detection and validation to translational research and clinical development. Sermonix Pharmaceuticals CEO and founder Dr David Portman stated: “At Sermonix, we believe patients deserve not only highly efficacious treatments but also ones that are well-tolerated and potentially improve quality of life for breast cancer patients. “Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone and cardiovascular health would be fulfilling on the promise of optimised drug development.” Sermonix’s Phase III asset, oral lasofoxifene, is currently in development for oestrogen receptor 1-mutated ER+ human epidermal growth factor receptor 2 (HER2)- metastatic breast cancers. The company is enrolling subjects to assess lasofoxifene in the ELAINE-3 trial, which compares the oral therapy in conjunction with the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor abemaciclib against fulvestrant + abemaciclib in pre-and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with mutations of oestrogen receptor 1.

Phase 3

24 Mar 2025

·www.prnewswire.com

Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics

Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced a strategic collaboration to optimize Regor's proprietary, cutting-edge rCARD™ (Regor Computer Accelerated Rational Discovery) platform for identification of novel targets and therapeutics that fulfill unmet patient clinical needs and preferences in the breast oncology arena. The partnership will unite the key core competencies of both organizations to leverage expertise from early discovery through preclinical, clinical, and commercial launch, resulting in treatments that deliver on the promise of fulfilling on efficacy but also developing therapies with tolerability and quality of life profiles that are aligned with patient priorities and concerns. With a Phase 3 asset – oral lasofoxifene – in development for the treatment of ESR1-mutated ER+ HER2- mBC, the Sermonix team has expertise within the clinical drug development and commercialization arena and understands the landscape and value proposition of new treatments, which are requirements for launch success and adoption by both patients and health care providers. Patient insights and unmet needs within the arena of onco-sexuality and cardio oncology, in addition to patient concerns with respect to bone health, have been increasing in importance and are areas for which Sermonix also has expertise and interest in exploring. These areas are currently gaps within the breast cancer treatment patient arena and hold great concern for patients as breast cancer potentially evolves from a lethal to a chronic disease. Regor's leading rCARD™ platform empowers drug discovery and development from target identification and validation, molecular design and optimization, to translational research and clinical development with unprecedented speed, efficiency, and success rate. "Regor's translational to clinical approach – and then confirmation of clinical impact – is one we greatly admire and is producing molecules for development that will be best in class from both an efficacy and tolerability perspective," said Dr. David Portman, Sermonix founder and chief executive officer. "At Sermonix, we believe patients deserve not only highly efficacious treatments, but also ones that are well tolerated and potentially improve quality of life for breast cancer patients. Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone, and cardiovascular health would be fulfilling on the promise of optimized drug development. It is an honor to collaborate with Regor in that shared mission." Sermonix is currently enrolling its Evaluation of Lasofox ife ne in ESR1 Mutations (ELAINE-3) study, comparing targeted lasofoxifene in combination with the CDK 4/6 inhibitor abemaciclib versus fulvestrant plus abemaciclib in pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. "After engaging in extensive discussions with Sermonix, closely watching its clinical and commercial market development efforts in the breast oncology segment, it is obvious the company shares the vision and dedication of our team at Regor," said Dr. Xiayang Qiu, founder and CEO of Regor. "The Sermonix team demonstrates both expertise and passion, and we are truly excited to embrace that as part of our work in identifying optimal drug candidates that can make a significant impact for patients with metastatic breast cancer." About Sermonix Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking a Phase 3 clinical study of lasofoxifene, its lead investigational drug. The Sermonix management team, led by founder Dr. David Portman, has significant experience in all stages of the drug development, regulatory and commercialization processes. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience at AstraZeneca in the breast cancer drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in nuclear receptor biology. Miriam Portman, M.D., is co-founder and chief operating officer, with expertise in clinical trial conduct and patient recruitment. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D., vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert's Pharmaceutical Division. Learn more at SermonixPharma.com. To learn more about the ELAINE studies, visit DiscoverElaine.com. Sermonix Contact: Elizabeth Attias, Sc.D. Chief Strategy and Development Officer [email protected] (973) 723-7832 About Regor Therapeutics Group Regor Therapeutics Group is a clinical-stage biotechnology company, headquartered in Cambridge, MA and with operations in Houston, TX, San Diego, CA, and Shanghai, China. Regor is developing innovative and clinically differentiated medicines to address large unmet needs in oncology, metabolism, and auto-immunity. Regor is powered by the highly efficient drug discovery engine rCARDTM (Regor Computer Accelerated Rational Discovery) that enables rapid prototyping and validation of candidate molecules. This rapid approach to developing small molecules against high-profile targets is the creation of the four cofounders who collectively brought decades of experience in leading US biopharma and were previously the named inventors of 4 FDA-approved medicines. The power of the rCARDTM platform and approach has been highlighted by out-licensing deals with top companies, including Roche/Genentech on next-gen CDK oncology agents RGT-419B and RGT-587 (now GDC-4198 and GDC-0587) in late 2024.To learn more about Regor, please visit us at . Regor Contact: Cece Wenqin Hu Communications & Corporate Affairs E: [email protected] SOURCE Sermonix Pharmaceuticals; Regor Therapeutics Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3License out/in

100 Deals associated with Abemaciclib

External Link

KEGG	Wiki	ATC	Drug Bank
D10688	Abemaciclib	L01XE50	DB12001

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced breast cancer	Canada	Eli Lilly Canada, Inc.	08 Apr 2019
Metastatic breast cancer	Canada	Eli Lilly Canada, Inc.	08 Apr 2019
HR Positive/HER2 Negative/Node positive breast cancer	European Union	Eli Lilly Nederland BV	26 Sep 2018
HR Positive/HER2 Negative/Node positive breast cancer	Iceland	Eli Lilly Nederland BV	26 Sep 2018
HR Positive/HER2 Negative/Node positive breast cancer	Liechtenstein	Eli Lilly Nederland BV	26 Sep 2018
HR Positive/HER2 Negative/Node positive breast cancer	Norway	Eli Lilly Nederland BV	26 Sep 2018
Hormone receptor positive HER2 negative breast cancer	United States	Eli Lilly & Co.	28 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Phase 3	United States	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	China	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Japan	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Argentina	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Australia	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Belgium	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Brazil	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Canada	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	Czechia	Eli Lilly & Co.	14 Apr 2022
Castration-sensitive prostate cancer	Phase 3	France	Eli Lilly & Co.	14 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Phase 2 study of letrozole, abemaciclib and metformin (AACR2025)	Phase 2	Recurrent Endometrial Cancer ER positive \| RB1 \| CCNE1 ... View more	25	Letrozole/Abemaciclib/Metformin	mkrybqfftn(ctwirgnwiq) = qdcjmoytwd drbxmvtwcm (wtepjssubm, 14.9% - 53.5) View more	Positive	29 Apr 2025
NCT04975308 (EMBER-3, Pubmed \| N Engl J Med)	Phase 3	Advanced breast cancer	874	Imlunestrant	xifgirlqrd(ssaiwivvqk) = ccqmzvacyg geletgsady (pzctpgclyy ) View more	Positive	27 Mar 2025
				Standard Therapy	xifgirlqrd(ssaiwivvqk) = bybvcspfcq geletgsady (pzctpgclyy ) View more
NCT04298983 (RAD 1805, CTgov)	Phase 2	Prostatic Cancer \| Adenocarcinoma of prostate	9	Androgen deprivation therapy (ADT)+Abemaciclib 150 MG by mouth twice daily	cmtbjpwali = ukzcnonztd dedofrhmka (wqyzycptot, ppmmiszuim - blbexfjsdl) View more	-	25 Mar 2025
NCT03706365 (CYCLONE 2, CTgov)	Phase 2/3	Metastatic castration-resistant prostate cancer	393	Prednisone+Abiraterone acetate+Abemaciclib (Abemaciclib)	aoracerofq(nwweedsbzt) = qeuevwjswz koyntnhoxp (ccchhaiaiv, piqzmibwmz - tgrhublssa) View more	-	25 Mar 2025
				Placebo+Prednisone+Abiraterone acetate (Placebo)	aoracerofq(nwweedsbzt) = hnqprmflws koyntnhoxp (ccchhaiaiv, iqitvebiwh - twtxeabodz) View more
NCT05169567 (postMONARCH, CTgov)	Phase 3	Hormone receptor positive HER2 negative breast cancer	368	Fulvestrant+Abemaciclib (Arm A: Abemaciclib Plus Fulvestrant)	zuhblnowpf(hkcfnabyzv) = rdkjpyfvzp rtwehlboyx (whodisnlvc, vwtckquaim - bafkdildml) View more	-	25 Mar 2025
				Placebo+Fulvestrant (Arm B: Placebo Plus Fulvestrant)	zuhblnowpf(hkcfnabyzv) = ztxjnqmdqa rtwehlboyx (whodisnlvc, crbxijzxwt - ujcaimtrwl) View more
NCT04256941 (CTgov)	Phase 2	Metastatic breast cancer	4	Fulvestrant (Fulvestrant)	mqrwbpoczh(uwcrxgkqfn) = dkyctgtijz bdkcdqxwyb (aijjzxjnge, bgdyuedmki - bsoyjmaabr) View more	-	25 Mar 2025
				fulvestrant+ribociclib (Kisqali)+abemaciclib (verzenio)+palbociclib (Ibrance) (Continuing AI After Randomization)	mqrwbpoczh(uwcrxgkqfn) = rmdvzepgol bdkcdqxwyb (aijjzxjnge, avplrkpyqq - xjkxkxumkp) View more
NCT05169567 (postMONARCH, Pubmed \| J Clin Oncol)	Phase 3	Advanced breast cancer ESR1 \| PIK3CA mutations	368	Abemaciclib + Fulvestrant	nggfdpnuez(uxipveikei) = exuptomfsk aiebdzipoe (uobyhuqhbw, 5.6 - 8.6) View more	Positive	20 Mar 2025
				Placebo + Fulvestrant	nggfdpnuez(uxipveikei) = wrdrsdhpit aiebdzipoe (uobyhuqhbw, 3.7 - 5.6) View more
NCT04975308 (EMBER-3, Pubmed \| SABCS2024) Manual	Phase 3	Advanced breast cancer	874	Imlunestrant	reqwwuaqhy(glmiuagaxh) = byxvsbmlzy xskfxpgctw (ccewcyasnr ) View more	Positive	11 Dec 2024
				Standard therapy	reqwwuaqhy(glmiuagaxh) = cvnqtkfoso xskfxpgctw (ccewcyasnr ) View more
NCT05563220 \| NCT05386108 (ELEVATE, SABCS2024) Manual	Phase 1/2	ER-positive/HER2-negative Breast Cancer HER2 Negative	55	Elacestrant + Abemaciclib (all efficacy-evaluable)	azmoguaufc(qywxzltusj) = rpxtjhevps ruxasxacax (hzxzmlnsxp )	Positive	10 Dec 2024
				Elacestrant + Abemaciclib (ESR1-mut population)	azmoguaufc(qywxzltusj) = idbssjgrdz ruxasxacax (hzxzmlnsxp )
NCT05548127 (TACTIVE-U, GlobeNewswire) Manual	Phase 1	ER-positive/HER2-negative Breast Cancer Third line	16	Vepdegestrant + Abemaciclib	qncxsmpsqb(tcveceiyvr) = None gvxkqgvqzm (ykwcmesbhx ) View more	Positive	10 Dec 2024
				Vepdegestrant + Abemaciclib (mutant ESR1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis